Core Viewpoint - The company Mengke Pharmaceutical-U (688373.SH) successfully held its second extraordinary general meeting of shareholders in 2025, where over 81% of votes approved a series of proposals including a private placement plan, strategic cooperation, and a three-year shareholder return plan, while nearly 80% of votes opposed the removal of current board members and executives [1][2]. Group 1 - The private placement plan involves Mengke Pharmaceutical issuing approximately 164 million A-shares at a price of 6.30 yuan per share, raising a total of no more than 1.033 billion yuan, aimed at funding project research and commercialization [2]. - Following the completion of the issuance, Hai Jing Pharmaceutical will hold 20% of Mengke Pharmaceutical's shares and will nominate more than half of the board members, thus becoming the controlling shareholder [2]. - The introduction of a strategic investor in the pharmaceutical sector is expected to optimize the governance structure, enhance profitability, and address funding bottlenecks, promoting sustainable development for the company [2]. Group 2 - The strategic cooperation agreement between Mengke Pharmaceutical and Hai Jing Pharmaceutical aims to leverage Mengke's expertise in anti-multidrug-resistant bacteria drugs and Hai Jing's mature R&D and production systems to enhance both companies' core competitiveness [3]. - The collaboration will focus on product commercialization, production synergy, R&D innovation interaction, and capital cooperation, utilizing existing market resources for deep commercialization efforts [3]. - If market resource integration proceeds smoothly, the projected sales revenue for Mengke's products is expected to reach 260 million yuan, 388 million yuan, and 600 million yuan in 2026, 2027, and 2028 respectively, representing significant growth from the 130 million yuan revenue in 2024 [3].